The durability of beta-interferon in reducing the conversion rate to multiple sclerosis of a first clinical demyelinating event is demonstrated

One of the fundamental tasks in the inflammatory arena is to prevent the conversion of a of an index event to a series. While there are many theories, over many years, the exact cause of multiple sclerosis (MS) is unknown. Despite having to peer through this mist, unparalled advances have been made over the last two decades with transformative treatments, usually with an anti-inflammatory basis. Yet if treatment could begin at the earliest of manifestations, then logic would dictate a better outcome. The clinically isolated syndrome (CIS) is this first point in …